Secondary endpoints
death, syncope, cardiac arrhythmia
RECURRENCE, CARDIAC ARRHYTHMIA
Within trial cost-effectiveness (cost per syncope avoided and cost per quality-adjusted life year (QALY) gained), and lifetime cost per QALY gained at (a) 1 year and (b) 2 years.Number of self-reported episodes of syncope at (a) 90 days and (b) 2 years, those identified in the medical records at (c) 90 days, (d) 1 year and (e) 2 years, and syncope recurrence rate at (f) 90 days, (g) 1 year and (h) 2 years.Index presentation hospital (a) admission rate and (b) duration of hospital stay.Patient satisfaction (measured using a patient questionnaire) at 1 year.Clinically significant cardiac arrhythmia (serious and/or symptomatic cardiac arrhythmia, (a) 30-day, (b) 1-year and (c) 2-year all-cause death.Detection of diagnostic ECG/symptom correlation (symptomatic) at (a) 90 days, (b) 1 year and (c) 2 years.Time to detect clinically significant cardiac arrhythmia (ie, time to clinician being aware).In the intervention group, duration of enhanced ambulatory ECG monitoring required to detect clinically significant cardiac arrhythmia.Number and type of diagnostic tests and therapeutic interventions at (a) 1 year and (b) 2 years.